IPCA Laboratories losing market share in anti-malarial products

Posted on May 10, 2018 Updated on May 10, 2018

Indian pharma market for anti-malarial products has shown declining trend over the last five years. Ipca, a leading player in anti-malarial products in India has also seen a downtrend in sales of these drugs. However, the trend in de-growth has been sharper in the industry when compared with a decline in IPCA’s revenue from anti-malaria products.

[Image 1: Compare screen shows anti-malarial products sales for the industry and IPCA]

[Image 2: Compare screen shows index for anti-malarial products sales for the industry and IPCA]

IPCA derives over 16% of revenues from anti-malaria products (Image 3). The company has maintained its position as a market leader in the domestic market for anti-malarial products with the share of ~50%. However, in recent months, IPCA’s market share has started dwindling marginally (Image 4).

Anti-malarial products account for 0.44% of the Indian pharma market while the average market share of the companies in this segment is pegged at 0.67%, which is fairly constant.

[Image 3: Therapeutic revenue contribution for IPCA]

[Image 4: Therapeutic market share for IPCA]

FiND collects, organizes and performs deep-dive analytics on structured and unstructured data sets to provide unique insights into companies, industries, and countries. Some of the key data sets that we offer for Pharmaceutical sector are litigation, new drug opportunity, detailed drug profile and clinical trial data from multiple locations.

To know more about FiND, email us at find@heckyl.com